FMT to Convert Response to Immunotherapy

Status Recruiting

Clinical Trial Summary

In this study the aim is to investigate whether transfer of the microbiota of either responder or non-responder patients via fecal microbiotica transplantation (FMT) can convert the response to immunotherapy in immune checkpoint inhibitors (ICI) refractory metastatic melanoma patients. This is a randomized double-blind intervention phase Ib/IIa trial in ICI refractory metastatic melanoma patients receiving either FMT of an ICI responding or FMT from an ICI non-responding donor, in combination with ICI. Following randomization, patients will receive vancomycin 250 mg, four times daily for 4 days (day -5 up until day -2), and undergo bowel clearance on day -1 (in total 1L MoviPrep). The FMT, either derived from donor group R (who showed a good response on anti-PD-1 therapy) or donor group NR (who showed progression on anti-PD-1 therapy), will be performed by a gastroenterologist using esophagogastroduodenoscopy. A total amount of 198mL (containing a total of 60 gram feces) will be used for transplantation. Anti-PD-1 treatment will be continued according to the patient's regular treatment schedule. Evaluation of safety and response to treatment will be performed.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05251389
Study type	Interventional
Source	The Netherlands Cancer Institute
Contact	John Haanen, Prof
Phone	+31205129111
Email	j.haanen@nki.nl
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	August 31, 2022
Completion date	April 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04330430` - Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (Stage IIIB/C/D-IV M1a) Melanoma With Injectable Disease	Phase 2
Withdrawn	`NCT04007588` - A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma	Phase 2
Recruiting	`NCT05171374` - pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
Completed	`NCT03620019` - Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma	Phase 2
Recruiting	`NCT04562129` - IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients	Phase 2
Recruiting	`NCT04990726` - Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors
Recruiting	`NCT05970497` - A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors	Phase 1
Recruiting	`NCT05370807` - A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma	Phase 2
Recruiting	`NCT04045691` - Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment
Not yet recruiting	`NCT05068453` - Study of Oncolytic Virus in Combination With HX-008 and Radiotherapy in Melanoma Patients With Liver Metastasis	Phase 1
Not yet recruiting	`NCT05070221` - Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis	Phase 1
Recruiting	`NCT03353402` - Fecal Microbiota Transplantation (FMT) in Metastatic Melanoma Patients Who Failed Immunotherapy	Phase 1
Recruiting	`NCT04513028` - Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma	N/A
Recruiting	`NCT05598853` - Intrathecal Double Checkpoint Inhibition	Phase 1
Recruiting	`NCT04521075` - A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC	Phase 1/Phase 2
Recruiting	`NCT06425926` - Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors	Phase 1/Phase 2
Completed	`NCT03153085` - A Study of Combination With TBI-1401(HF10) and Ipilimumab in Japanese Patients With Unresectable or Metastatic Melanoma	Phase 2
Recruiting	`NCT04741997` - Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma	Early Phase 1
Recruiting	`NCT03991130` - High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma	Phase 2
Active, not recruiting	`NCT04526899` - Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma	Phase 2